Fresh Tracks Therapeutics Inc.
Fresh Tracks Therapeutics, Inc. does not have significant operations. Previously, the company was engaged in the development of various prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases in the United States. Fresh Tracks Therapeutics, Inc. was founded in 2009 and is headquartered in Boulder, Colorado.
Fresh Tracks Therapeutics Inc. (FRTX) - Total Assets
Latest total assets as of December 2023: $11.59 Million USD
Based on the latest financial reports, Fresh Tracks Therapeutics Inc. (FRTX) holds total assets worth $11.59 Million USD as of December 2023.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Fresh Tracks Therapeutics Inc. - Total Assets Trend (1990–2023)
This chart illustrates how Fresh Tracks Therapeutics Inc.’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Fresh Tracks Therapeutics Inc. - Asset Composition Analysis
Current Asset Composition (December 2023)
Fresh Tracks Therapeutics Inc.'s total assets of $11.59 Million consist of 99.7% current assets and 0.3% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 93.8% |
| Accounts Receivable | $45.00K | 0.4% |
| Inventory | $545.00K | 4.7% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (1990–2023)
This chart illustrates how Fresh Tracks Therapeutics Inc.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Fresh Tracks Therapeutics Inc.'s current assets represent 99.7% of total assets in 2023, an increase from 59.1% in 1990.
- Cash Position: Cash and equivalents constituted 93.8% of total assets in 2023, up from 56.8% in 1990.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 9.0% in 1990.
- Asset Diversification: The largest asset category is inventory at 4.7% of total assets.
Fresh Tracks Therapeutics Inc. Competitors by Total Assets
Key competitors of Fresh Tracks Therapeutics Inc. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Fresh Tracks Therapeutics Inc. - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Moderate asset utilization - Fresh Tracks Therapeutics Inc. generates 0.69x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Fresh Tracks Therapeutics Inc. is currently not profitable relative to its asset base.
Fresh Tracks Therapeutics Inc. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 6.98 | 3.28 | 18.39 |
| Quick Ratio | 6.65 | 3.44 | 18.39 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $9.90 Million | $ 7.01 Million | $ 43.84 Million |
Fresh Tracks Therapeutics Inc. - Advanced Valuation Insights
This section examines the relationship between Fresh Tracks Therapeutics Inc.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.56 |
| Latest Market Cap to Assets Ratio | 0.26 |
| Asset Growth Rate (YoY) | 12.8% |
| Total Assets | $11.59 Million |
| Market Capitalization | $2.98 Million USD |
Valuation Analysis
Below Book Valuation: The market values Fresh Tracks Therapeutics Inc.'s assets below their book value (0.26 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Fresh Tracks Therapeutics Inc.'s assets grew by 12.8% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Fresh Tracks Therapeutics Inc. (1990–2023)
The table below shows the annual total assets of Fresh Tracks Therapeutics Inc. from 1990 to 2023.
| Year | Total Assets | Change |
|---|---|---|
| 2023-12-31 | $11.59 Million | +12.80% |
| 2022-12-31 | $10.27 Million | -65.44% |
| 2021-12-31 | $29.72 Million | -11.65% |
| 2020-12-31 | $33.63 Million | +85.37% |
| 2019-12-31 | $18.14 Million | -65.34% |
| 2018-12-31 | $52.34 Million | -34.97% |
| 2017-12-31 | $80.49 Million | +53.96% |
| 2016-12-31 | $52.28 Million | +4.75% |
| 2015-12-31 | $49.91 Million | -13.91% |
| 2014-12-31 | $57.98 Million | -12.62% |
| 2013-12-31 | $66.35 Million | -31.26% |
| 2012-12-31 | $96.52 Million | +40.35% |
| 2011-12-31 | $68.77 Million | -5.67% |
| 2010-12-31 | $72.91 Million | +8.22% |
| 2009-12-31 | $67.37 Million | +14.08% |
| 2008-12-31 | $59.06 Million | -34.80% |
| 2007-12-31 | $90.58 Million | -27.68% |
| 2006-12-31 | $125.25 Million | +32.50% |
| 2005-12-31 | $94.53 Million | -6.61% |
| 2004-12-31 | $101.23 Million | -8.56% |
| 2003-12-31 | $110.71 Million | -14.46% |
| 2002-12-31 | $129.43 Million | -16.23% |
| 2001-12-31 | $154.49 Million | -5.16% |
| 2000-12-31 | $162.90 Million | +261.20% |
| 1999-12-31 | $45.10 Million | +0.67% |
| 1998-12-31 | $44.80 Million | -11.64% |
| 1997-12-31 | $50.70 Million | -3.24% |
| 1996-12-31 | $52.40 Million | -4.90% |
| 1995-12-31 | $55.10 Million | +81.85% |
| 1994-12-31 | $30.30 Million | -13.68% |
| 1993-12-31 | $35.10 Million | +194.96% |
| 1992-12-31 | $11.90 Million | +376.00% |
| 1991-12-31 | $2.50 Million | -43.18% |
| 1990-12-31 | $4.40 Million | -- |